Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHGE Stock Forecast 2025-2026
$5.17
Current Price
$7.89M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PHGE Price Targets
+9,455.1%
To High Target of $494.00
+7,617.6%
To Median Target of $399.00
+5,780.1%
To Low Target of $304.00
PHGE Price Momentum
+22.2%
1 Week Change
-32.5%
1 Month Change
-55.4%
1 Year Change
-62.7%
Year-to-Date Change
-76.6%
From 52W High of $22.06
+26.1%
From 52W Low of $4.10
📊 TOP ANALYST CALLS
Did PHGE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BiomX is one of their latest high-conviction picks.
Latest PHGE Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, PHGE has a bullish consensus with a median price target of $399.00 (ranging from $304.00 to $494.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $5.17, the median forecast implies a 7,617.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHGE Analyst Ratings
2
Buy
0
Hold
0
Sell
PHGE Price Target Range
Low
$304.00
Average
$399.00
High
$494.00
Current: $5.17
Latest PHGE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHGE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 26, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 25, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| May 16, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $15.00 |
| Apr 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $21.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $21.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $2.00 |
| Jan 8, 2025 | HC Wainwright& Co. | Buy | Maintains | $N/A | |
| Aug 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| May 28, 2024 | Laidlaw & Co. | Yale Jen | Buy | Initiates | $2.50 |
| May 21, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Apr 22, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Apr 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Mar 7, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Aug 9, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| May 15, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $7.00 |
| Nov 10, 2022 | Chardan Capital | Buy | Maintains | $N/A | |
| May 24, 2022 | Chardan Capital | Buy | Maintains | $N/A |
BiomX Inc. (PHGE) Competitors
The following stocks are similar to BiomX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BiomX Inc. (PHGE) Financial Data
BiomX Inc. has a market capitalization of $7.89M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -154.5%.
Valuation Metrics
Market Cap
$7.89M
Enterprise Value
$26.17M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+87.7%
Current Ratio
1.7x
Debt/Equity
62.8x
ROE
-154.5%
ROA
-48.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
BiomX Inc. (PHGE) Business Model
About BiomX Inc.
What They Do
Develops innovative microbiome treatments using phage technology.
Business Model
BiomX operates as a clinical-stage biotechnology company, generating revenue through the discovery and development of bacteriophage-based therapies aimed at treating diseases linked to microbiome imbalances. The company leverages its proprietary platform to identify bacterial targets and corresponding phages quickly, enhancing its pipeline for customizable treatments, which may attract partnerships and licensing agreements with larger pharmaceutical companies.
Additional Information
BiomX addresses significant healthcare challenges, including antibiotic resistance, and positions itself as a leader in precision medicine and sustainable healthcare solutions. Its focus on innovative therapies may provide substantial growth opportunities and investor interest in the evolving biotech landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
52
CEO
Mr. Jonathan Eitan Solomon MBA
Country
Israel
IPO Year
N/A
Website
www.biomx.comBiomX Inc. (PHGE) Latest News & Analysis
Latest News
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
12 days ago
Quick Summary
BiomX Inc. (NYSE: PHGE) reported that the FDA is still evaluating the nebulizer device for drug delivery in its Phase 2b trial of BX004 for cystic fibrosis patients.
Why It Matters
FDA evaluation of BiomX's nebulizer device impacts trial outcomes and regulatory approval, influencing potential market success and stock performance for PHGE.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
The Company is collaborating with a third-party manufacturer to respond to FDA inquiries needed to lift the clinical hold on the nebulizer device in its Phase 2b trial.
Why It Matters
The FDA's clinical hold on the nebulizer device could delay trial progress, impacting the company's timeline and potential revenue, affecting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX Inc. (PHGE) will hold its Q3 2025 earnings call on November 12, 2025, at 8:30 AM EST, featuring CFO Marina Wolfson and CEO Jonathan Solomon.
Why It Matters
The Q3 2025 earnings call for BiomX Inc. will provide insights into the company's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The FDA has provided positive feedback on BX011, targeting S. aureus in Diabetic Foot Infections, confirming a clear clinical pathway following prior Phase 2 success.
Why It Matters
Positive FDA feedback enhances BX011's market potential, indicating a higher likelihood of approval and successful commercialization, which could significantly boost the company's stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX has addressed the FDA's concerns regarding the third-party nebulizer for BX004 and responded to a request for additional technical clarifications.
Why It Matters
BiomX's resolution of FDA queries on BX004's nebulizer boosts regulatory confidence, potentially accelerating product approval and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
3 months ago
Quick Summary
The U.S. FDA has issued a clinical hold on BiomX's Phase 2b study to review data on a third-party nebulizer for delivering BX004, with no concerns noted about the drug itself.
Why It Matters
The FDA's clinical hold on BiomX's study may delay product development, impacting timelines and investor confidence, though no issues were reported with the BX004 drug itself.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHGE Stock
What is BiomX Inc.'s (PHGE) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, BiomX Inc. (PHGE) has a median price target of $399.00. The highest price target is $494.00 and the lowest is $304.00.
Is PHGE stock a good investment in 2026?
According to current analyst ratings, PHGE has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.17. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHGE stock?
Wall Street analysts predict PHGE stock could reach $399.00 in the next 12 months. This represents a 7,617.6% increase from the current price of $5.17. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is BiomX Inc.'s business model?
BiomX operates as a clinical-stage biotechnology company, generating revenue through the discovery and development of bacteriophage-based therapies aimed at treating diseases linked to microbiome imbalances. The company leverages its proprietary platform to identify bacterial targets and corresponding phages quickly, enhancing its pipeline for customizable treatments, which may attract partnerships and licensing agreements with larger pharmaceutical companies.
What is the highest forecasted price for PHGE BiomX Inc.?
The highest price target for PHGE is $494.00 from at , which represents a 9,455.1% increase from the current price of $5.17.
What is the lowest forecasted price for PHGE BiomX Inc.?
The lowest price target for PHGE is $304.00 from at , which represents a 5,780.1% increase from the current price of $5.17.
What is the overall PHGE consensus from analysts for BiomX Inc.?
The overall analyst consensus for PHGE is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $399.00.
How accurate are PHGE stock price projections?
Stock price projections, including those for BiomX Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 4:34 PM UTC